-+ 0.00%
-+ 0.00%
-+ 0.00%

TenNor Therapeutics Enrolls First Patient in Phase IIb Rifaquizinone Trial for Prosthetic Joint Infection

PUBT·11/12/2026 09:59:37
Listen to the news
TenNor Therapeutics Enrolls First Patient in Phase IIb Rifaquizinone Trial for Prosthetic Joint Infection
  • TenNor Therapeutics announced Nov. 12, 2026, that its Phase IIb rifaquizinone trial enrolled its first patient with prosthetic joint infection.
  • The trial evaluates intra-articular treatment without debridement or revision surgery, following positive Phase IIa proof-of-concept results.
  • Rifasutenizol completed supplementary submissions for Chinese marketing review following an August 2025 application and a June 2026 request for additional information.
  • Phase III rifasutenizol results for Helicobacter pylori infection were already published in The Lancet Infectious Diseases on Sept. 11, 2025.
  • Research findings were also presented at the 2025 Digestive Disease Week conference in the US.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tennor Therapeutics (Suzhou) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261112-12409523), on November 12, 2026, and is solely responsible for the information contained therein.